Cancer Therapy: New Targets for Chemotherapy

References

• Szekeres, T. and Novotny, L. (2002) "New targets and drugs in cancer chemotherapy", Med. Princ. Pract. 11, 117–125.
   PubMed Web of Science ®Google Scholar
• Verma, M. and Srivastava, S. (2002) "Epigenetics in cancer: implications for early detection and prevention", Lancet Oncol. 3, 755–763.
   PubMed Web of Science ®Google Scholar
• Kondo, Y., Shen, L. and Issa, J.P. (2003) "Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer", Mol. Cell Biol. 23, 206–215.
   PubMed Web of Science ®Google Scholar
• Shi, H., Maier, S., Nimmrich, I., Yan, P.S., Caldwell, C.W., Olek, A. and Huang, T.H. (2003) "Oligonucleotide-based microarray for DNA methylation analysis: principles and applications", J. Cell. Biochem. 88, 138–143.
   PubMed Web of Science ®Google Scholar
• Leone, G., Teofili, L., Voso, M.T. and Lubbert, M. (2002) "DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias", Haematologica 87, 1324–1341.
   PubMed Web of Science ®Google Scholar
• Nguyen, CT., Weisenberger, D.J., Velicescu, M., Gonzales, F.A., Lin, J.C., Liang, G. and Jones, P.A. (2002) "Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine", Cancer Res. 62, 6456–6461.
   PubMed Web of Science ®Google Scholar
• Kaneda, A., Kaminishi, M., Yanagihara, K., Sugimura, T. and Ushijima, T. (2002) "Identification of silencing of nine genes in human gastric cancers", Cancer Res. 62, 6645–6650.
   PubMed Web of Science ®Google Scholar
• Lusher, ME., Lindsey, J.C., Latif, F., Pearson, A.D., Ellison, D.W. and Clifford, S.C. (2002) "Biallelic epigenetic inacti-vation of the RASSF1A tumor suppressor gene in medullo-blastoma development", Cancer Res. 62, 5906–5911.
   PubMed Web of Science ®Google Scholar
• Zhong, S., Tang, MN., Yeo, W., Liu, C., Lo, Y.M. and Johnson, P.J. (2002) "Silencing of GSTP1 gene by CpG island DNA hypermethylation in HBV-associated hepatocellular carci-nomas", Clin. Cancer Res. 8, 1087–1092.
   PubMed Web of Science ®Google Scholar
• Zhang, Y.J., Ahsan, H., Chen, Y., Lurm, R.M., Wang, L.Y., Chen, S.Y., Lee, PH., Chen, C.J. and Santella, R.M. (2002) "High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma", Mol. Carcinog. 35, 85–92.
   PubMed Web of Science ®Google Scholar
• Sigalotti, L., Coral, S., Nardi, G., Spessotto, A., Cortini, E., Cattarossi, I., Colizzi, F., Altomonte, M. and Maio, M. (2002) "Promoter methylation controls the expression of MAGE2, 3 and 4 genes in human cutaneous melanoma", J. Immunother. 25, 16–26.
   PubMed Web of Science ®Google Scholar
• Kuerbitz, S.J., Pahys, J., Wilson, A., Compitello, N. and Gray, T.A. (2002) "Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia", Carcinogenesis 23, 559–564.
   PubMed Web of Science ®Google Scholar
• Esteller, M., Gaidano, G., Goodman, S.N., Zagonel, V, Capello, D., Botto, B., Rossi, D., Gloghini, A., Vitolo, U., Carbone, A., Baylin, S.B. and Herman, J.G. (2002) "Hyper-methylation of the DNA repair gene 0(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma", J. Natl Cancer Inst. 94, 26–32.
   PubMed Web of Science ®Google Scholar
• van Noesel, M.M., van Bezouw, S., Salomons, G.S., Voute, PA., Pieters, R., Baylin, S.B., Herman, J.G. and Versteeg, R. (2002) "Tumor-specific down-regulation of the tumor necrosis factor-related apoptosis-inducing ligand decoy receptors DcR1 and DcR2 is associated with dense promoter hypermethylation", Cancer Res. 62, 2157–2161.
   PubMed Web of Science ®Google Scholar
• Moinova, H.R., Chen, W.D., Shen, L., Smiraglia, D., Olechnowicz, J., Ravi, L., Kasturi, L., Myeroff, L., Plass, C., Parsons, R., Minna, J., Willson, J.K., Green, S.B., Issa, J.P. and Markowitz, S.D. (2002) "HUFF gene silencing in human colon cancer", Proc. Natl Acad. Sci. USA 99, 4562–4567.
   PubMed Web of Science ®Google Scholar
• Kim, W.J., Vo, Q.N., Shrivastav, M., Lataxes, TA. and Brown, K.D. (2002) "Aberrant methylation of the ATM promoter correlates with increased radiosensitivity in a human colo-rectal tumor cell line", Oncogene 21, 3864–3871.
   PubMed Web of Science ®Google Scholar
• Brown, R. and Strathdee, G. (2002) "Epigenetic cancer therapies: DNA methyltransferase inhibitors", Expert Opin. Investig. Drugs 11, 747–754.
   Web of Science ®Google Scholar
• Brown, R. and Strathdee, G. (2002) "Epigenomics and epigenetic therapy of cancer", Trends Mol. Med. 8 (Suppl.), S43—S48.
   PubMedGoogle Scholar
• Stewart, S.A. and Hahn, W.C. (2002) "Prospects for anti-neoplastic therapies based on telomere biology", Curr. Cancer Drug Targets 2, 1–17.
   PubMed Web of Science ®Google Scholar
• Tentori, L., Portarena, I., Barbarino, M., Balduzzi, A., Levati, L., Vergati, M., Biroccio, A., Gold, B., Lombardi, M.L. and Graziani, G. (2003) "Inhibition of telomerase increases resistance of melanoma cells to temozolomide, but not to temozolomide combined with poly (ADP-ribose) polymerase inhibitor", Mol. Pharmacol. 63, 192–202.
   PubMed Web of Science ®Google Scholar
• Rezler, E.M., Bearss, D.J. and Hurley, L.H. (2002) "Telomeres and telomerases as drug targets", Curr. Opin. Pharmacol. 2, 415–423.
   PubMed Web of Science ®Google Scholar
• Ruffini, EA., Biragyn, A. and Kwak, L.W. (2002) "Recent advances in multiple myeloma immunotherapy", Biomed. Pharmacother. 56, 129–132.
   PubMed Web of Science ®Google Scholar
• Gowan, S.M., Harrison, JR., Patterson, L., Valenti, M., Read, M.A., Neidle, S. and Kelland, L.R. (2002) "A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity", Mol. Pharmacol. 61, 1154–1162.
   PubMed Web of Science ®Google Scholar
• Murakami, C., Takemura, M., Sugiyama, Y., Kamisuki, S., Asahara, H., Kawasaki, M., Ishidoh, T., Linn, S., Yoshida, S., Sugawara, E, Yoshida, H., Sakaguchi, K. and Mizushina, Y. (2002) "Vitamin A-related compounds, all-trans retinal and retinoic acids, selectively inhibit activities of mammalian replicative DNA polymerases", Biochim. Biophys. Acta 1574, 85–92.
   PubMed Web of Science ®Google Scholar
• Boonsong, A., Curran, S., McKay, J.A., Cassidy, J., Murray, G.I. and McLeod, H.L. (2002) "Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases", Hum. Pathol. 33, 1114–1119.
   PubMed Web of Science ®Google Scholar
• Niitsu, N., Higashihara, M. and Honma, Y. (2002) "The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukemia", Exp. Hematol. 30, 1273–1282.
   PubMed Web of Science ®Google Scholar
• Bridewell, D.J., Finlay, G.J. and Baguley, B.C. (2001) "Topoisomerase I/II selectivity among derivatives of N[2-(dimethylamino)ethyllacridine-4-carboxamide (DACA)", Anticancer Drug Des. 16, 317–324.
   PubMedGoogle Scholar
• Lima, C.M. and Joppert, M.G. (2002) "Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer", Oncology (Huntingt.) 16\(Suppl. 9), 25–31.
   Web of Science ®Google Scholar
• Mok, T.S., Wong, H., Zee, B., Yu, K.H., Leung, T.W., Lee, T.W., Yim, A., Chan, A.T., Yeo, W., Chak, K. and Johnson, P. (2002) "A Phase I—II study of sequential administration of topotecan and oral etoposide (topoisomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma", Cancer 95, 1511–1519.
   PubMed Web of Science ®Google Scholar
• Berney, D.M., Shamash, J., Gaffney, J., Jordan, S. and Oliver, R.T. (2002) "DNA topoisomerase I and II expression in drug resistant germ cell tumours", Br. J. Cancer 87, 624–629.
   PubMed Web of Science ®Google Scholar
• Peters, K.B. and Brown, J.M. (2002) "Tirapazamine: a hypoxia-activated topoisomerase II poison", Cancer Res. 62, 5248–5253.
   PubMed Web of Science ®Google Scholar
• Pourquier, P., Gioffre, C., Kohlhagen, G., Urasaki, Y., Goldwasser, E, Hertel, L.W., Yu, S., Pon, R.T., Gmeiner, W.H. and Pommier, Y. (2002) "Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I", Clin. Cancer Res. 8, 2499–2504.
   PubMed Web of Science ®Google Scholar
• Mainwaring, M.G., Rimsza, L.M., Chen, SF, Gomez, S.P., Weeks, F.W., Reddy, V, Lynch, J., May, W.S., Kahn, S., Moreb, J., Leather, H., Braylan, R., Rowe, T.C., Fieniewicz, K.J. and Wingard, J.R. (2002) "Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan fol-lowed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels", Leuk. Lymphoma 43, 989–999.
   PubMed Web of Science ®Google Scholar
• Yoshizawa, K., Cioca, D.P., Kawa, S., Tanaka, E. and Kiyosawa, K. (2002) "Peroxisome proliferator-activated receptor gamma ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines", Cancer 95, 2243–2251.
   PubMed Web of Science ®Google Scholar
• Curtin, J.F. and Cotter, T.G. (2002) "Anisomycin activates JNK and sensitizes DU 145 prostate carcinoma cells to Fas mediated apoptosis", Br. J. Cancer 87, 1188–1194.
   PubMed Web of Science ®Google Scholar
• Yamamoto, T. and Tanigawa, N. (2001) "The role of survivin as a new target of diagnosis and treatment in human cancer", Med. Electron Microsc. 34, 207–212.
   PubMedGoogle Scholar
• Liu, T., Raetz, E., Moos, P.J., Perkins, S.L., Bruggers, CS., Smith, E and Carroll, W.L. (2002) "Diversity of the apoptotic response to chemotherapy in childhood leukemia", Leukemia 16, 223–232.
   PubMed Web of Science ®Google Scholar
• Van Ophoven, A., Ng, C.P., Patel, B., Bonavida, B. and Belldegrun, A. (1999) "Tumor necrosis factor-related apopto-sis-inducing ligand (TRAIL) for treatment of prostate cancer: first results and review of the literature", Prostate Cancer Prostatic Dis. 2, 227–233.
   PubMed Web of Science ®Google Scholar
• Kelly, M.M., Hoel, B.D. and Voelkel-Johnson, C. (2002) "Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression", Cancer Biol. Ther. 1, 520–527.
   PubMed Web of Science ®Google Scholar
• Ng, C.P., Zisman, A. and Bonavida, B. (2002) "Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance", Prostate 53, 286–299.
   PubMed Web of Science ®Google Scholar
• Jin, Z., Dicker, D.T. and El-Deiry, W.S. (2002) "Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL", Cell Cycle 1, 82–89.
   PubMed Web of Science ®Google Scholar
• Naka, T., Sugamura, K., Hylander, B.L., Widmer, M.B., Rustum, Y.M. and Repasky, E.A. (2002) "Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice", Cancer Res. 62, 5800–5806.
   PubMed Web of Science ®Google Scholar
• Munshi, A., Mcdonnell, T.J. and Meyn, R.E. (2002) "Chemo-therapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells", Cancer Chemot her. Pharmacol. 50, 46–52.
   PubMed Web of Science ®Google Scholar
• Schlitzer, M. (2002) "Structure based design of benzo-phenone-based non-thiol farnesyltransferase inhibitors", Curr. Pharm. Des. 8, 1713–1722.
   PubMed Web of Science ®Google Scholar
• Midgley, R.S. and Kerr, D.J. (2002) "Ras as a target in cancer therapy", Crit. Rev. Oncol. Hematol. 44, 109–120.
   PubMed Web of Science ®Google Scholar
• Smith, V, Rowlands, M.G., Barrie, E., Workman, P. and Kelland, L.R. (2002) "Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line", Clin. Cancer Res. 8, 2002–2009.
   PubMed Web of Science ®Google Scholar
• Wong, W.W., Dimitroulakos, J., Minden, M.D. and Penn, L.Z. (2002) "HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis", Leukemia 16, 508–519.
   PubMed Web of Science ®Google Scholar
• Frassanito, M.A., Cusmai, A., Piccoli, C. and Dammacco, F. (2002) "Manumycin inhibits farnesyltransferase and induces apoptosis of drug-resistant interleukin 6-producing myeloma cells", Br. J. Haematol. 118, 157–165.
   PubMed Web of Science ®Google Scholar
• Wick, B. and Groner, B. (1997) "Evaluation of cell surface antigens as potential targets for recombinant tumor toxins", Cancer Lett. 118, 161–172.
   PubMed Web of Science ®Google Scholar
• Ottaiano, A., Pisano, C., De Chiara, A., Ascierto, P.A., Botti, G., Barletta, E., Apice, G., Gridelli, C. and Iaffaioli, V.R. (2002) "CD40 activation as potential tool in malignant neoplasms", Tumori 88, 361–366.
   PubMed Web of Science ®Google Scholar
• Green, S.K., Karlsson, M.C., Ravetch, J.V. and Kerbel, R.S. (2002) "Disruption of cell—cell adhesion enhances antibody-dependent cellular cytotmdcity: implications for antibody-based therapeutics of cancer", Cancer Res. 62, 6891–6900.
   PubMed Web of Science ®Google Scholar
• French, J.J., Cresswell, J., Wong, W.K., Seymour, K., Charnley, R.M. and Kirby, J.A. (2002) "T cell adhesion and cytolysis of pancreatic cancer cells: a role for E-cadherin in immuno-therapy?", Br. J. Cancer 87, 1034–1041.
   PubMed Web of Science ®Google Scholar
• Szekeres, T., Sedlak, J. and Novotny, L. (2002) "Benzamide riboside, a recent inhibitor of inosine 5-monophosphate dehydrogenase induces transferrin receptors in cancer cells", Curr. Med. Chem. 9, 759–764.
   PubMed Web of Science ®Google Scholar
• Nabel, E.G. (2002) "CDKs and CKIs: molecular targets for tissue remodeling", Nat. Rev. Drug Discov. 1, 587–598.
   PubMed Web of Science ®Google Scholar
• Carnero, A. (2002) "Targeting the cell cycle for cancer therapy", Br. J. Cancer 87, 129–133.
   PubMed Web of Science ®Google Scholar
• Turini, M.E. and DuBois, R.N. (2002) "Cyclooxygenase-2: a therapeutic target", Annu. Rev. Med. 53, 35–57.
   PubMed Web of Science ®Google Scholar
• Lin, D.T., Subbaramaiah, K., Shah, J.P., Dannenberg, A.J. and Boyle, JD. (2002) "Cyclooxygenase-2: a novel molecular target for the prevention and treatment of head and neck cancer", Head Neck 24, 792–799.
   PubMed Web of Science ®Google Scholar
• Jiang, X.H., Lam, S.K., Lin, M.C., Jiang, S.H., Kung, H.F., Slosberg, ED., Soh, J.W., Weinstein, I.B. and Wong, B.C. (2002) "Novel target for induction of apoptosis by cyclo-oxygenase-2 inhibitor SC-236 through a protein kinase C-beta(1)-dependent pathway", Oncogene 21, 6113–6122.
   PubMed Web of Science ®Google Scholar
• Howe, L.R. and Dannenberg, A.J. (2002) "A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer", Semin. Oncol. 29\(Suppl. 11), 111–119.
   PubMedGoogle Scholar
• Dang, C.T., Shapiro, C.L. and Hudis, C.A. (2002) "Potential role of selective COX-2 inhibitors in cancer management", Oncology (Huntingt.) 16\(Suppl. 4), 30–36.
   PubMedGoogle Scholar
• Krishnaiah, YS., Satyanarayana, V., Kumar, B.D. and Karthikeyan, R.S. (2002) "Studies on the development of colon-targeted delivery systems for celecoxib in the prevention of colorectal cancer", J. Drug Target 10, 247–254.
   PubMed Web of Science ®Google Scholar
• Kundu, N. and Fulton, A.M. (2002) "Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer", Cancer Res. 62, 2343–2346.
   PubMed Web of Science ®Google Scholar
• Waskewich, C., Blumenthal, R.D., Li, H., Stein, R., Goldenberg, D.M. and Burton, J. (2002) "Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hema-topoietic and epithelial cell lines", Cancer Res. 62, 2029–2033.
   PubMed Web of Science ®Google Scholar